GTx (GTXI) Ramps Higher After FDA Removes Full Clinical Hold for Capesaris
Tweet
Share
E-mailGet Alerts GTXI Hot Sheet
Join SI Premium – FREE
GTx, Inc. (Nasdaq: GTXI) said the FDA removed its Full Clinical Hold on Investigational New Drug application for Capesaris following the review by the FDA of the complete response and its new Phase II clinical protocol.
GTx plans to initiate during the third quarter this Phase II open label clinical study of 75 men with metastatic castration resistant prostate cancer to test three lower doses of Capesaris (125 mg, 250 mg and 500 mg) sequentially in cohorts of 25 patients each.
Shares are trading up 25% on the news.
GTx plans to initiate during the third quarter this Phase II open label clinical study of 75 men with metastatic castration resistant prostate cancer to test three lower doses of Capesaris (125 mg, 250 mg and 500 mg) sequentially in cohorts of 25 patients each.
Shares are trading up 25% on the news.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Milestone Pharmaceuticals starts Phase 3 AFib-RVR trial for etripamil
- Trans Canada Gold wraps up phase 1 drilling at Harrison Lake project
- FDA grants Nuvation Bio fast track status for brain cancer drug
Create E-mail Alert Related Categories
FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
